MorphoSys Presents Comprehensive Pipeline and Technology Update at R&D Day in London

By The Associated Press Thursday, November 25, 2023

newsvine diigo google
slashdot
Share
Loading...

MorphoSys AG / MorphoSys Presents Comprehensive Pipeline and Technology Update at R&D Day in London Processed and transmitted by Thomson Reuters. The issuer is solely responsible for the content of this announcement.

Multiple Sclerosis Announced as Second Indication for MOR103

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will present significant recent developments and provide a full outlook on its partnered and proprietary drug pipeline as well as a comprehensive technology update during today's R&D Day to be held in London starting at 9.30 am GMT. A second event will be held in New York on November 29, 2010 starting at 11.30 am EST. MorphoSys has built one of the broadest antibody pipelines in the biotechnology industry with 12 clinical projects ongoing and a total of 76 distinct drug programs.

Today's event will be held at Berenberg's offices at 60 Threadneedle Street, London, EC2R 8HP, UK and can be viewed via webcast at www.morphosys.com (http://www.morphosys.com) . The New York event will be held at The W Hotel, 541 Lexington Avenue, New York, NY 10022, USA and registration is possible at www.morphosys.com/rnd-day2010 (http://www.morphosys.com/rnd-day2010) .

New Announcements at Today's R&D Day include:

… Disclosure of multiple sclerosis as the second indication for the Company's lead development program MOR103, a fully human HuCAL antibody targeting GM- CSF. The decision is based on a compelling scientific rationale and promising pre-clinical data. MorphoSys expects to start a phase 1b trial in multiple sclerosis with MOR103 in H2 2011.

… Preclinical data for MOR103 in both rheumatoid arthritis (RA) and multiple sclerosis and an update on imaging/biomarkers used in the ongoing phase 1b/2a study in RA.

… Preclinical data for MOR202, a HuCAL antibody targeting CD38 to treat multiple myeloma. A clinical trial application (CTA) to initiate a phase 1/2a trial with MOR202 in patients with relapsed/refractory myeloma has been filed in Europe and the Company expects to dose the first patient in H1 2011.

… An update on MOR208, an Fc-enhanced anti-CD19 antibody to treat B-cell malignancies. The program was in-licensed from Xencor in June 2010 and is currently in a phase 1 clinical trial in relapsed or refractory CLL/SLL in the US with patient enrollment expected imminently.

… An update on the Company's partnered pipeline, comprising now five partnered projects in phase 2 clinical trials. Roche has started a phase 2 clinical trial with Gantenerumab, a HuCAL antibody against amyloid-beta to treat Alzheimer's disease.

… The latest technology developments, such as the recently announced optimization platform arYla, as well as additional modules for more efficient selection and screening of antibody libraries.

"MorphoSys has established a significant proprietary product portfolio and its clinical programs MOR103, MOR202 and MOR208 are on track to generate lucrative out-licensing opportunities in the years ahead," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys. "Our decision to develop MOR103 in a second indication beyond rheumatoid arthritis, namely multiple sclerosis, is based on a compelling scientific rationale and promising pre- clinical data and we are intrigued by its prospects. I'm excited about the progress we've made in Proprietary Development since I joined MorphoSys two years ago."

"The commercial opportunity for therapeutic antibodies is enormous. As we learn more about this class of drugs we are identifying ways of making antibodies that will be superior to currently available drugs, and our strategy is to command and apply a range of technologies to deliver these new therapies." commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys. "MorphoSys has now established a suite of technologies to enable generation of the best possible therapeutic antibodies and continues to set industry standards with its new arYla antibody optimization technology."

MorphoSys will hold a public conference call today at 09:30 GMT (10:30 CET) to give an update on its partnered pipeline, proprietary portfolio and recent technology developments.

Dial-in number for the Conference Call (listen-only):

Germany: +49 (0) 89 24443 2975

For U.K. residents: +44 (0) 20 3003 2666

For U.S. residents: +1 212 999 6659

Please dial in 10 minutes before the beginning of the conference. In addition, MorphoSys offers participants the opportunity to follow the presentation through a simultaneous slide presentation online athttp://www.morphosys.com.

A live webcast, slides, webcast replay and transcript will be made available at http://www.morphosys.com (http://www.morphosys.com) .

About MorphoSys: MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM- CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visithttp://www.morphosys.com/

HuCAL@, HuCAL GOLD@, HuCAL PLATINUM@, CysDisplay@ and RapMAT@ are registered trademarks of MorphoSys. arYla is a trademark of MorphoSys.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

HUG‥1465353

--- End of Message ---

MorphoSys AG Lena-Christ-Str. 48 Martinsried / Munchen Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP; Listed: Freiverkehr in Borse Stuttgart, Freiverkehr in Hanseatische Wertpapierborse zu Hamburg, Freiverkehr in Borse Berlin, Freiverkehr in Borse Dusseldorf, Freiverkehr in Bayerische Borse Munchen, Freiverkehr in Niedersachsische Borse zu Hannover, Prime Standard in Frankfurter Wertpapierborse, Regulierter Markt in Frankfurter Wertpapierborse;

Press Release (PDF): http://hugin.info/130295/R/1465353/403558.pdf (http://hugin.info/130295/R/1465353/403558.pdf)

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Bringing the Cell Image into Focus

Nov 2

Improvements in transmission electron microscope (TEM) technology increase the power of this imaging tool for the study of cell biology.

Finding a Cure for Spinal Cord Injury with On-Demand LIMS

Oct 25

The Miami Project to Cure Paralysis finds an on-demand laboratory information management system (LIMS) helps to accelerate discovery in its HCS projects.

Saving Cells: Image Processing for Improved Viability, Part II: Iterative Deconvolution

Oct 25

3D light microscopy and deconvolution provide a means to investigate 3D structure, providing near-confocal quality images without the temporal requirements or potentially damaging phototoxicity associated with other 3D imaging technologies. This article is Part II in a series regarding viability, resolution improvement, and measurement in fluorescence imaging. Part I focused on spectral unmixing.

Saving Cells: Image Processing for Improved Viability

Sep 22

This article is Part I of a two-part series regarding viability, resolution improvement, and measurement in fluorescence imaging. Part II will focus on deconvolution.

HP Scalable Network Storage Systems for Life Sciences

Sep 13

Life sciences research today is advancing exponentially, each step bringing us closer to the realization of truly personalized medicine–preventive care and treatments designed specifically for each individual. In the near future, PCPGM healthcare researchers expect to be able to use predictive genetic testing to create custom treatment plans for individuals and deliver dramatic improvements over today’s one-size-fits-all approach. But research capabilities are only part of the equation; current storage and operating capacities must also evolve to accommodate ever-expanding amounts of data before the goal of personalized medicine can be realized.

Step up to the MIQE

Mar 30

Over the years, polymerase chain reaction (PCR) has evolved into a readily automated, high throughput quantitative technology. Real-time quantitative PCR (qPCR) has become the industry standard for the detection and quantification of nucleic acids for multiple application, including quantification of RNA levels. But a lack of consensus among researchers on how to best perform and interpret qPCR experiments presents a major hurdle for advancement of the technology. This problem is exacerbated by insufficient experimental detail in published work, which impedes the ability of others to accurately evaluate or replicate reported results.

Fast Optimization of a Multiplex Influenza Identification Panel Using a Thermal Gradient

Mar 30

The year 2009 was marked by the emergence of a novel influenza A (H1N1) virus that infects humans. There is a need to identify the different strains of influenza virus for purposes of monitoring the H1N1 strain pandemic and for other epidemiological and scientific purposes.

Advantages of Monolithic Laser Combiner Technology in Confocal Microscopy Systems

Jan 6

Fluorescence microscopy techniques require a reliable light source at the desired wavelength or wavelengths, with minimal downtime for maintenance and alignment. Lasers are a popular light source, although the alignment and upkeep of laser combiners is a time-consuming prospect for many users.

Using the Tecan Genesis Workstation to Automate a Cytometric Bead Array (CBA) Immunoassay

Mar 11

The poster describe the process involved in automating a Cytometric Bead Array (CBA) immunoassay developed to measure relative concentrations of serum antibodies against Tetanus (TT), Sperm Whale Myoglobin (SWM) and Keyhole Limpet Hemocyanin (KLH) in KLH-immunized volunteers.

Ensuring Quality in Assays Performed with Automated Liquid Handlers

Feb 2

The focus of this presentation is to highlight the need of ensuring quality in important assays performed with automated liquid handlers. Nearly all assays performed within a laboratory are volume-dependent. In turn, all concentrations of biological and chemical components in these assays, as well as the associated dilution protocols, are volume-dependent. Because analyte concentration is volume-dependent, an assay’s results might be falsely interpreted if liquid handler variability and inaccuracies are unknown or if the system(s) go unchecked for a long period.

Inkjet System for Protein Crystallography

Feb 1

X-ray crystallography is used routinely by scientists to obtain the three dimensional structure of a biological molecule of interest.Such information can be used to determine how a pharmaceutical interacts with a protein target and what changes might improve functionality. However, the crystallization of macromolecules still remains a serious hindrance in structural determination despite impressive advances in screening methods and technologies.

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Nov 9 2009

Action selection is modulated by external stimuli either directly or via memory retrieval. In a constantly changing environment, animals have evolved attention-like processes to effectively filter the incoming sensory stream. These attention-like processes, in turn, are modulated by memory. The neurobiological nature of how attention, action selection and memory are inter-connected is unknown. We describe here new phenotypes of the memory mutant radish in the fruit fly Drosophila.

Normalizing effect of plant-originated glycoprotein (116 kDa) on G(0)/G (1) arrest in cadmium chloride-induced primary cultured mouse myelocytes.

1 hour ago

Cadmium chloride is a well-known carcinogenic and immunotoxic metal chemical, which is commonly found in cigarette smoke and industrial effluent and which is able to cause cell cycle arrest in various cell lines. This study demonstrated that glycoprotein...

Do the diagnostic criteria for ADHD need to change? Comments on the preliminary proposals of the DSM-5 ADHD and Disruptive Behavior Disorders Committee.

1 hour ago

The purpose of this commentary is to discuss the recent proposals for revision of the diagnostic criteria made by the DSM-5 ADHD and Disruptive Behavior Disorders Committee. The major concerns with the current diagnostic criteria for ADHD and hence the main...

Universal Alcohol/Drug Screening in Prenatal Care: A Strategy for Reducing Racial Disparities? Questioning the Assumptions.

1 hour ago

Agencies and organizations promoting universal screening for alcohol and drug use in prenatal care argue that universal screening will reduce White versus Black racial disparities in reporting to Child Protective Services (CPS) at delivery. Yet, no published...

Construction and functional screening of a metagenomic library using a T7 RNA polymerase-based expression cosmid vector.

1 hour ago

The metagenomic approach has greatly accelerated the discovery of new enzymes by giving access to the genetic potential of microorganisms from various environments. Function-based screening depends on adequate expression of the foreign genes in the heterologous...

Prokariotic Cell Collection in Denmark

Nov 6 2009

I would like to know about a prokariotic cell collection in Denmark. Is there a cell bank in this country? I need a Lactobacillus strain for a fermentation assay and this information about the bank is very helpful for me.

Request for Entries

Oct 16 2009

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   

MULTIMEDIA

Video:

Viewing SureFocus Slides

Jun 11

A demonstration of SureFocus Microscope Slides in the review of AFB Smears. SureFocus Slides are a patent-pending breakthrough in tuberculosis detection, as their fluorescent staining circle remains visible during review, Fluorescence Microscopy.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14 2009

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.

Information: